Hepatitis C, Chronic  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

60 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
HEPCAT, NCT01125189 / 2010-018295-24: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Checkmark COMMAND-1
Aug 2014 - Aug 2014: COMMAND-1
Checkmark EASL 2013: COMMAND 1
Apr 2013 - Apr 2013: EASL 2013: COMMAND 1
Checkmark AASLD 2012: COMMAND-1
More
Completed
2b
558
US, Canada, Europe, RoW
Daclatasvir, Placebo, peg-interferon alfa-2a, Pegasys, ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
04/12
08/12
NCT01257204 / 2010-022408-28: Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Checkmark
Oct 2014 - Oct 2014: 
Checkmark AGW 2013: COMMAND GT2/3
Sep 2013 - Sep 2013: AGW 2013: COMMAND GT2/3
Checkmark EASL 2013: COMMAND GT2/3
More
Completed
2b
196
US, Canada, Europe, RoW
Placebo, Daclatasvir, BMS-790052, Pegylated interferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
05/12
09/12
HEPCAT, NCT01170962 / 2010-019378-34: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Completed
2b
512
US, Canada, Europe, RoW
BMS-790052, Placebo, peginterferon alfa-2a, Pegasys®, ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
06/12
12/12
NCT01271790 / 2010-023952-10: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed
2b
245
US, Europe
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Gilead Sciences
Hepatitis C, Chronic
01/13
09/13
NCT01225380 / 2010-020911-35: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2b
324
US, Canada, Europe
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Gilead Sciences
Chronic Hepatitis C Infection
01/13
09/13
NCT01516918 / 2011-004150-26: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Completed
2b
103
US, Canada, Europe
VX-222, telaprevir, Incivek, VX-950, Incivo, ribavirin, Copegus, peginterferon-alfa-2a, Pegasys
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
09/13
12/13
D-LITE, NCT01795911: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed
2b
165
US
Pegylated Interferon Lambda, BMS-914143, Ribasphere, Ribavirin, Daclatasvir, BMS-790052
Bristol-Myers Squibb
Hepatitis C
04/14
09/14
D-LITE, NCT01309932 / 2010-022568-11: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE
More
Completed
2b
165
Japan, US, Europe, RoW
Pegylated Interferon Lambda (pegIFNλ), BMS-914143, BMS-790052 (NS5A Inhibitor), BMS-790052, Ribavirin (RBV), Ribasphere, BMS-650032 (NS3 Protease Inhibitor), BMS-650032, Pegylated Interferon Alfa-2a (pegIFNα-2a), Pegasys®, Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo for BMS-650032, Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for BMS-790052, Placebo for Ribavirin (RBV), Placebo for Ribasphere
Bristol-Myers Squibb
Hepatitis C
07/14
09/14
NCT01030432 / 2009-013652-69: Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Checkmark
Jul 2014 - Jul 2014: 
Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark
More
Completed
2a/2b
285
US, Europe, RoW
BMS-650032, Placebo, Pegasys, Peginterferon Alfa-2a, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
10/12
10/12
NCT00528528 / 2007-001044-44: An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed
2a
166
Europe
Telaprevir, Peg-IFN-alfa-2a, Peg-IFN-alfa-2b, Ribavirin (RBV) tablet, Ribavirin (RBV) capsule
Tibotec BVBA
Chronic Hepatitis C
07/09
08/09
NCT00874770 / 2009-010149-29: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Checkmark Data-AASLD
Oct 2011 - Oct 2011: Data-AASLD
Checkmark Data
Mar 2011 - Mar 2011: Data
Completed
2a
74
US, Europe
Daclatasvir, Placebo, Peginterferon alpha-2a, Pegasys, ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Infection
11/09
01/11
NCT01142700: A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Withdrawn
2a
0
US
BMS-824393, Placebo, Peginterferon Alpha-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Chronic Hepatitis C Virus Genotype 1
12/10
12/10
HEPCAT, NCT01193361: Ph IIA Study (SOC +/- NS5B)

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2a
39
US
BMS-791325, Placebo, Peg-interferon alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
06/11
11/12
NCT01017575: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Checkmark
Jan 2014 - Jan 2014: 
Checkmark
Jan 2014 - Jan 2014: 
Completed
2a
55
Japan
Daclatasvir, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Infection
10/11
10/11
NCT00433069: Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Completed
2
5
Europe
Pioglitazone, Actos, Interferon Alfa-2a, Pegasys, Ribavirin, Copegus
University Hospital, Geneva
Chronic Hepatitis C
12/07
01/08
NCT00336479: Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Completed
2
263
US
Telaprevir, VX-950, Ribavirin, RBV, Pegylated Interferon Alfa 2a, Peg-IFN-alfa-2a, Placebo
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
02/08
02/08
NCT00372385 / 2006-000828-14: Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Completed
2
334
Europe
Ribavirin, Pegylated Interferon Alfa 2a, Placebo, Telaprevir, VX-950
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
05/08
06/08
NCT00377182: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Completed
2
107
US
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Hoffmann-La Roche
Hepatitis C, Chronic
08/08
08/08
PIFNPK, NCT00085917: Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Completed
2
29
US
Double dose pegylated interferon with weight based Ribavirin, Pegasys, standard dose pegylated interferon alfa -2a and ribavirin, pegasys
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
11/08
11/08
NCT00561353 / 2007-003289-16: A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Completed
2
121
Europe
TMC435, Placebo, Peginterferon (PegIFNα-2a), PEGASYS, Ribavirin, COPEGUS
Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic
12/08
05/10
NCT00517439 / 2006-006604-11: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Checkmark P2 data
Dec 2011 - Dec 2011: P2 data
Completed
2
516
US, Canada, Europe, RoW
Copegus, Pegasys, RO4588161
Hoffmann-La Roche
Hepatitis C, Chronic
01/10
01/10
STEALTHC-2, NCT00495391: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Completed
2
64
US
Nitazoxanide, Alinia, Placebo, Peginterferon alfa-2a, PEGASYS, Ribavirin, COPEGUS
Romark Laboratories L.C.
Chronic Hepatitis C
02/10
02/10
NCT00720434: A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Completed
2
35
US
PF-00868554, Placebo
Pfizer
Hepatitis C
03/10
03/10
NCT02716779 / 2006-000935-86: Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

Completed
2
68
Europe
Pegylated Interferon (PEG-IFN) alfa-2a, Pegasys®, Placebo, Ribavirin, Copegus®
Hoffmann-La Roche, Roche Pharma AG
Hepatitis C, Chronic
04/10
04/10
NCT00537407: A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Completed
2
50
US
Debio 025, Alisporivir, Peg-IFNα2a, PEGASYS, Ribavirin, Copegus
Debiopharm International SA
Chronic Hepatitis C
04/10
04/10
STEALTHC-3, NCT00637923: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Completed
2
112
US
Nitazoxanide, Alinia, Placebo, Peginterferon alfa-2a, PEGASYS, Ribavirin, COPEGUS
Romark Laboratories L.C.
Chronic Hepatitis C
04/10
04/10
NCT01054729: Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Completed
2
64
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, Placebo, PEG, Pegasys®, RBV, Copegus®
Gilead Sciences
Hepatitis C
04/10
08/11
NCT01011166: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Completed
2
81
US
IDX184, Placebo, Peginterferon alfa-2a (Peg-IFN), Pegasys, Ribavirin (RBV)
Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
07/10
07/10
NCT00854802 / 2008-004605-34: A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Checkmark AASLD 2011
Oct 2011 - Oct 2011: AASLD 2011
Checkmark EASL 2011
Mar 2011 - Mar 2011: EASL 2011
Completed
2
290
Europe
Debio 025, Alisporivir, Peg-IFNα2a, Pegasys, Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole, Debio 025 placebo
Debiopharm International SA, Parexel
Chronic Hepatitis C
09/10
09/10
NCT01072695 / 2009-013690-18: Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

Checkmark EASL 2012
Mar 2011 - Mar 2011: EASL 2012
Completed
2
46
Europe
GS-9256, GS-9190, Ribavirin, COPEGUS, Peginterferon alfa-2a, Pegasys
Gilead Sciences
HCV Infection
10/10
01/12
PEGIFN, NCT01140997: Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Completed
2
211
RoW
Ypeginterferon alfa-2b, Peginterferon alfa-2b, Peginterferon alfa-2a, Pegasys
Xiamen Amoytop Biotech Co., Ltd., Peking University People's Hospital
Chronic Hepatitis C
01/11
03/12
NCT00944684: High Dose Ribavirin in the Treatment of Chronic Hepatitis C

Completed
2
32
Europe
High ribavirin dose, Standard ribavirin dose
University of Bern, Roche Pharma AG, University of Lausanne, Cantonal Hospital of St. Gallen, Waid City Hospital, Zurich, University of Basel
Chronic Hepatitis C
04/11
04/11
NCT01439373: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Completed
2
16
US
GSK2336805, Pegylated interferon alfa-2a, Pegasys, Ribavirin, GSK2336805 Matching Placebo, Placebo
GlaxoSmithKline, PPD
Hepatitis C, Chronic
12/11
12/11
NCT00963885 / 2009-009608-38: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Checkmark
Jul 2013 - Jul 2013: 
Checkmark AASLD 2011: ATLAS
Oct 2011 - Oct 2011: AASLD 2011: ATLAS
Completed
2
229
US, Canada, Europe, RoW
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Hoffmann-La Roche
Hepatitis C, Chronic
01/12
01/12
NCT01273948: Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

Completed
2
66
RoW
Bavituximab, Bavituxmab, Pegylated interferon (PEG-IFN), Pegasys
Peregrine Pharmaceuticals
Hepatitis C
01/12
02/12
NCT00869661 / 2008-008258-21: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Checkmark PROPEL & JUMP-C
Mar 2014 - Mar 2014: PROPEL & JUMP-C
Checkmark EASL data
Apr 2012 - Apr 2012: EASL data
Completed
2
413
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048
Hoffmann-La Roche
Hepatitis C, Chronic
02/12
02/12
NCT00704405 / 2008-000150-12: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark
Oct 2013 - Oct 2013: 
Checkmark APASL 2013
More
Completed
2
285
NA
Vaniprevir, MK-7009, Pegylated Interferon (Peg-IFN), PEGASYS™, Ribavirin (RBV), COPEGUS™, Placebo (PBO)
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
03/12
09/12
NCT01057667: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Checkmark PROPEL & JUMP-C
Mar 2014 - Mar 2014: PROPEL & JUMP-C
Checkmark Data-EASL
Apr 2012 - Apr 2012: Data-EASL
Completed
2
168
US, Canada
RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis C, Chronic
04/12
04/12
NCT01329978: Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

Checkmark Sofosbuvir+pegylated interferon alfa-2a+ribavirin(ATOMIC)
Mar 2013 - Mar 2013:  Sofosbuvir+pegylated interferon alfa-2a+ribavirin(ATOMIC)
Checkmark ATOMIC
Oct 2012 - Oct 2012: ATOMIC
Completed
2
332
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, RBV, Copegus®, PEG, Pegasys®
Gilead Sciences
Hepatitis C, Chronic
08/12
08/12
NCT01012895: Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark In patients previously failed SOC
More
Completed
2
215
US, Europe
BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Chronic Hepatitis C
10/12
02/14
INFORM-SVR, NCT01278134 / 2010-022067-35: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1

Checkmark
May 2014 - May 2014: 
Checkmark EASL 2012: INFORM-SVR
Apr 2012 - Apr 2012: EASL 2012: INFORM-SVR
Completed
2
170
US, Europe, RoW
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
10/12
10/12
NCT00606086 / 2007-005385-12: Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Completed
2
140
US
GI-5005, Pegasys and Ribavirin, Pegylated Interferon and Ribavirin
GlobeImmune
Genotype 1 Chronic Hepatitis C
11/12
11/12
NCT01220947 / 2010-019584-10: A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Checkmark AASLD 2012: DAUPHINE
Oct 2012 - Oct 2012: AASLD 2012: DAUPHINE
Completed
2
421
US, Canada, Europe, RoW
Copegus, Danoprevir, Pegasys, Ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
12/12
12/12
NCT01331850 / 2010-019585-90: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Checkmark MATTERHORN
Sep 2014 - Sep 2014: MATTERHORN
Checkmark AASLD 2012: MATTERHORN
Oct 2012 - Oct 2012: AASLD 2012: MATTERHORN
Completed
2
381
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
01/13
01/13
NCT01371604 / 2011-001878-25: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Checkmark IDX-184+/-(P+R)
Jun 2012 - Jun 2012: IDX-184+/-(P+R)
Completed
2
68
US
IDX184, Peginterferon alfa-2a (Peg-IFN), Pegasys, Ribavirin (RBV), Placebo
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
03/13
10/14
NCT01903954: A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Completed
2
283
US
peginterferon alfa-2a [Pegasys], placebo, ribavirin [Copegus], setrobuvir, ANA598
Hoffmann-La Roche
Hepatitis C, Chronic
05/13
05/13
NCT01289496: Ribavirin Dose Optimization for the Treatment of Hepatitis C

Completed
2
13
Canada
Peg-interferon alpha-2a, Ribavirin, Peg-interféron alpha-2a (PEGASYS), Ribavirin (COPEGUS)
Centre hospitalier de l'Université de Montréal (CHUM), Hoffmann-La Roche, Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Chronic Hepatitis C
08/13
08/13
NCT01908335: A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Completed
2
212
RoW
PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis C
08/13
07/14
TelapreVIH, NCT01332955: Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Checkmark ANRS HC26 TelapreVIH
Aug 2014 - Aug 2014: ANRS HC26 TelapreVIH
Checkmark CROI 2014: ANRS HC26 TelapreVIH
Mar 2014 - Mar 2014: CROI 2014: ANRS HC26 TelapreVIH
Checkmark CROI 2014: ANRS HC26 TelapreVIH
More
Completed
2
70
Europe
Telaprevir, VX-950, pegIFN alfa-2a, peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®, Rebetol®
ANRS, Emerging Infectious Diseases, Janssen-Cilag Ltd.
Hepatitis C, Chronic, HIV Infection
09/13
09/13
NCT01483742 / 2011-004129-28: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Completed
2
43
US, Canada, Europe, RoW
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
09/13
09/13
NCT01260350: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Checkmark EASL 2014: ELECTRON
Mar 2014 - Mar 2014: EASL 2014: ELECTRON
Checkmark APASL 2014: ELECTRON
Mar 2014 - Mar 2014: APASL 2014: ELECTRON
Checkmark HepDART 2013: LONESTAR & ELECTRON
More
Completed
2
292
RoW
SOF, Sovaldi®, GS-7977, PSI-7977, RBV, Copegus®, PEG, Pegasys®, LDV, GS-5885, GS-9669, LDV/SOF, Harvoni®
Gilead Sciences
Chronic Hepatitis C Infection
10/13
12/13
NCT01482403 / 2011-002714-37: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Completed
2
58
US, Canada, Europe
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Hoffmann-La Roche
Hepatitis C, Chronic
01/14
01/14
NCT01482390 / 2011-002715-28: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Completed
2
80
US, Canada, Europe
Ribavirin, Copegus, Mericitabine, Peginterferon Alfa-2a, Pegasys, Placebo, Telaprevir
Hoffmann-La Roche
Hepatitis C
01/14
01/14
NCT01579019: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn
2
0
US
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
03/14
03/14
NCT01648140: Dose Ranging of GSK2336805 in Combination Therapy

Completed
2
286
US, Europe
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Pegasys, Ribavirin, Ribasphere, Telaprevir, Incivek (United States), Incivo (European Union)
GlaxoSmithKline, PPD
Hepatitis C, Chronic
07/14
07/14
NCT01428063 / 2011-000836-27: Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Completed
2
276
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Asunaprevir, BMS-650032, Pegylated interferon alfa-2a, pegIFNα-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus Infection
09/14
12/14
NCT01749150: A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Completed
2
61
RoW
danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
02/15
02/15
NCT02216045: Effect of Camel Milk on Chronic Hepatitis C

Completed
2
40
RoW
Peginterferon, Ribavirin, camel milk, PEGASYS® COPEGUS®. Dromedary milk (camel milk ), Peginterferon, Ribavirin, PEGASYS® (Peginterferon ) , COPEGUS® (Ribavirin)
Mashhad University of Medical Sciences
Chronic Hepatitis C
02/15
02/15
NCT01826981: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Completed
2
359
RoW
LDV/SOF, Harvoni®, GS-5885/GS-7977, SOF, GS-7977, Sovaldi®, RBV, Peg-IFN, Pegasys®, GS-9669, VEL, GS-5816
Gilead Sciences
Chronic Hepatitis C
03/15
05/15
NCT01194037: A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

Completed
1b/2a
30
US
recombinant variant of interferon-alpha 2b, Hanferon, Peginterferon alfa-2a, Pegasys
HanAll BioPharma Co., Ltd.
Chronic Hepatitis C Infection, Genotype 1
05/12
06/12

Download Options